A Clinical Trial to Evaluate the Safety and Efficacy of AL2846 Capsules in Chinese Patients With Type I Neurofibromatosis
Status:
Recruiting
Trial end date:
2024-12-30
Target enrollment:
Participant gender:
Summary
AL2846 is a multi-target receptor tyrosine kinase inhibitor. The purpose of this study is to
evaluate the safety and efficacy of AL2846 capsules in Chinese patients with type I
neurofibromatosis (NF1) (neurofibromas and malignant peripheral nerve sheath tumors).